Improving Bone Health by Optimizing the Anabolic Action of Wnt Inhibitor Multitargeting
ABSTRACT Sclerostin antibody (romosozumab) was recently approved for clinical use in the United States to treat osteoporosis. We and others have explored Wnt‐based combination therapy to disproportionately improve the anabolic effects of sclerostin inhibition, including cotreatment with sclerostin a...
Guardat en:
| Autors principals: | , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Oxford University Press
2021-05-01
|
| Col·lecció: | JBMR Plus |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1002/jbm4.10462 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|